Research programme: short interfering RNA-based therapeutics - Silence Therapeutics

Drug Profile

Research programme: short interfering RNA-based therapeutics - Silence Therapeutics

Alternative Names: GalNAc-siRNA - Silence Therapeutics; ICS-283; Research programme: RNAi-based therapeutics -Intradigm/Qiagen

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Intradigm Corporation
  • Developer Intradigm Corporation; OPKO Health; Silence Therapeutics
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Acromegaly; Alcoholism; Cardiovascular disorders; Iron overload; Metabolic disorders
  • Discontinued Age-related macular degeneration; Cancer; Coronavirus infections; Diabetic retinopathy

Most Recent Events

  • 15 Aug 2017 Silence Therapeutics receives notice of allowance from the US PTO for US patent applications for its chemical modification technology
  • 16 May 2017 Silence Therapeutics files for patent protection for short interfering RNA-based therapeutics in USA and Europe
  • 28 Mar 2017 Silence Therapeutics has patents pending for siRNA delivery in USA and other countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top